Gilead Sciences reports a passive stake in Aspen Neuroscience (ASPE).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Gilead Sciences, Inc. has reported a passive investment in Aspen Neuroscience, Inc. (ASPE), acquiring 2,879,996 shares, which represents a 9.9% stake in the company's common stock. This disclosure was made via a Schedule 13G SEC filing, indicating Gilead holds sole voting and dispositive power over these shares. The filing was accepted by the SEC on November 6, 2026, at 05:34 PM EST.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.